|Part of a series on|
|Doping in sport|
Gene doping is the hypothetical non-therapeutic use of gene therapy in order to improve athletic performance in competitive sporting events. As of April 2015[update], there is no evidence that gene doping has been used for athletic performance-enhancement in any sporting events. Gene doping would involve the use of gene transfer to increase or decrease gene expression and protein biosynthesis of a specific human protein; this could be done by directly injecting the gene carrier into the person, or by taking cells from the person, transfecting the cells, and administering the cells back to the person.
The historical development of interest in gene doping by athletes and concern about the risks of gene doping and how to detect it moved in parallel with the development of the field of gene therapy, especially with the publication in 1998 of work on a transgenic mouse overexpressing insulin-like growth factor 1 that was much stronger than normal mice, even in old age, preclinical studies published in 2002 of a way to deliver erythropoietin (EPO) via gene therapy, and publication in 2004 of the creation of a "marathon mouse" with much greater endurance than normal mice, created by delivering the gene expressing PPAR gamma to the mice. The scientists generating these publications were all contacted directly by athletes and coaches seeking access to the technology. The public became aware of that activity in 2006 when such efforts were part of the evidence presented in the trial of a German coach.
Scientists themselves, as well as bodies including the World Anti-Doping Agency (WADA), the International Olympics Committee, and the American Association for the Advancement of Science, started discussing the risk of gene doping in 2001, and by 2003 WADA had added gene doping to the list of banned doping practices, and shortly thereafter began funding research on methods to detect gene doping.
The history of concern about the potential for gene doping follows the history of gene therapy, the medical use of genes to treat diseases, which was first clinically tested in the 1990s. Interest by the athletic community was especially spurred by the creation in a university lab of a "mighty mouse", created by administering a virus carrying the gene expressing insulin-like growth factor 1 to mice; the mice were stronger and remained strong even as they aged, without exercise. The lab had been seeking treatments for muscle wasting diseases, but when their work was made public, the lab was inundated with calls from athletes seeking the treatment, with one coach offering his whole team. The scientist told The New York Times in 2007: "I was quite surprised, I must admit. People would try to entice me, saying things like, ‘It’ll help advance your research.’ Some offered to pay me." He also told the Times that every time similar research is published he gets calls and that he explains that, even should the treatment became ready for use in people, which would take years, there would be serious risks, including death; he also said that even after he explains this, the athletes still want it.
In 1999, the field of gene therapy was set back when Jesse Gelsinger died in a gene therapy clinical trial, suffering a massive inflammatory reaction to the drug. This led regulatory authorities in the US and Europe to increase safety requirements in clinical trials even beyond the initial restrictions that had been put in place at the beginning of the biotechnology era to deal with the risks of recombinant DNA.
In June 2001, Theodore Friedmann, one of the pioneers of gene therapy, and Johann Olav Koss an Olympic gold medallist in speed skating, published a paper that was the first public warning about gene doping. Also in June 2001, a Gene Therapy Working Group, convened by the Medical Commission of the International Olympic Committee noted that "we are aware that there is the potential for abuse of gene therapy medicines and we shall begin to establish procedures and stateof-the-art testing methods for identifying athletes who might misuse such technology."
Research was published in 2002 about a preclinical gene therapy called Repoxygen, which delivered the gene encoding erythropoietin (EPO) as a potential treatment for anemia. The scientists from that company also received calls from athletes and coaches. In that same year the World Anti-Doping Agency held its first meeting to discuss the risk of gene doping, and the US President’s Council on Bioethics discussed gene doping in the context of human enhancement at several sessions.
In 2003, the field of gene therapy took a step forward and a step back; first gene therapy drug was approved, Gendicine, which was approved in China for the treatment of certain cancers, but children in France who had seemingly been effective treated with gene therapy for Severe combined immunodeficiency (non-human) began developing leukemia. In 2003 the BALCO scandal became public, in which chemists, trainers and athletes conspired to evade doping controls with new and undetectable doping substances. In 2003 the World Doping Agency proactively added gene doping to the list of banned doping practices. Also in 2003, a symposium convened by the American Association for the Advancement of Science focused on the issue.
Research published in 2004 showing that mice given gene therapy coding for a protein called PPAR gamma had about double the endurance of untreated mice and were dubbed "marathon mice"; those scientists received calls from athletes and coaches. Also in 2004 the World Anti-Doping Agency began to fund research to detect gene doping, and formed a permanent expert panel to advise it on risks and to guide the funding.
In 2006 interest from athletes in gene doping received widespread media coverage due its mention during the trial of a German coach who was accused and found guilty of giving his athletes performance enhancing drugs without their knowledge; an email in which the coach attempted to obtain Repoxygen was read in open court by a prosecutor. This was the first public disclosure that athletes were interested in gene doping.
As the field of gene therapy has developed, the risk of gene doping becoming a reality has increased with it.
There are numerous genes of interest as agents for gene doping. They include erythropoietin, insulin-like growth factor 1, human growth hormone, myostatin, vascular endothelial growth factor, fibroblast growth factor, endorphin, enkephalin and Alpha-actinin-3.
The risks of gene doping would be similar to those of gene therapy: immune reaction to the native protein leading to the equivalent of an genetic disease, massive inflammatory response, cancer, and death, and in all cases, these risks would be undertaken for short-term gain as opposed to treating a serious disease.
Alpha-actinin-3 is found only in skeletal muscle in humans, and has been identified in several genetic studies as having a different polymorphism in world-class athletes compared with normal people. One form that causes the gene to make more protein is found in sprinters and is related to increased power; another form that causes the gene to make less protein is found in endurance athletes. Gene doping agents could be designed with either polymorphism, or for endurance athletes, some DNA construct that interfered with expression like a small interfering RNA.
See also: Myostatin-related muscle hypertrophy
Myostatin is a protein responsible for inhibiting muscle differentiation and growth. Removing the myostatin gene or otherwise limiting its expression leads to an increase in muscle size and power. This has been demonstrated in knockout mice lacking the gene that were dubbed "Schwarzenegger mice". Humans born with defective genes can also serve as "knockout models"; a German boy with a mutation in both copies of the myostatin gene was born with well-developed muscles. The advanced muscle growth continued after birth, and the boy could lift weights of 3 kg at the age of 4. In work published in 2009, scientists administered follistatin via gene therapy to the quadricepts of non-human primates, resulting in local muscle growth similar to the mice.
Erythropoietin is a glycoprotein that acts as a hormone, controlling red blood cell production. Athletes have injected the EPO protein as a performance-enhancing substance for many years (blood doping). When the additional EPO increases the production of red blood cells in circulation, this increases the amount of oxygen available to muscle, enhancing an athlete's endurance. Recent studies suggest it may be possible to introduce another EPO gene into an animal in order to increase EPO production endogenously. EPO genes have been successfully inserted into mice and monkeys, and were found to increase hematocrits by as much as 80 percent in those animals. However, the endogonous and transgene derived EPO elicited autoimmune responses in some animals in the form of severe anemia.
Insulin-like growth factor 1
Insulin-like growth factor 1 is a protein involved in the mediation of the growth hormone. Administration of IGF-1 to mice has resulted in more muscle growth and quicker muscle and nerve regeneration. If athletes were to use this the sustained production of IGF-1 could cause heart disease and cancer.
Modulating the levels of proteins that affect psychology are also potential goals for gene doping; for example pain perception depends on endorphins and enkephalins, response to stress depends on BDNF, and an increase in synthesis of monamines could improve the mood of athletes. Preproenkephalin has been administered via gene therapy using a replication-deficient herpes simplex virus, which targets nerves, to mice with results good enough to justify a Phase I clinical trial in people with terminal cancer with uncontrolled pain. Adopting that approach for athletes would be problematic since the pain deadening would likely be permanent.
VEGF has been tested in clinical trials to increase blood flow and has been considered as a potential gene doping agent; however long term follow up of the clinical trial subjects showed poor results. The same is true of fibroblast growth factor. Glucagon-like peptide-1 increases the amount of glucose in the liver and has been administered via gene therapy to the livers of mouse models of diabetes and was shown to increase gluconeogenesis' for athletes this would make more energy available and reduce the buildup of lactic acid.
The World Anti-Doping Agency (WADA) is the main regulatory organization looking into the issue of the detection of gene doping. Both direct and indirect testing methods are being researched by the organization. Directly detecting the use of gene therapy usually requires the discovery of recombinant proteins or gene insertion vectors, while most indirect methods involve examining the athlete in an attempt to detect bodily changes or structural differences between endogenous and recombinant proteins.
Indirect methods are by nature more subjective, as it becomes very difficult to determine which anomalies are proof of gene doping, and which are simply natural, though unusual, biological properties. For example, Eero Mäntyranta, an Olympic cross country skier, had a mutation which made his body produce abnormally high amounts of red blood cells. It would be very difficult to determine whether or not Mäntyranta's red blood cell levels were due to an innate genetic advantage, or an artificial one.
A 2016 review found that about 120 DNA polymorphisms had been identified in the literature related to some aspect of athletic performance, 77 related to endurance and 43 related to power. 11 had been replicated in three or more studies and six were identified in genome-wide association studies, but 29 had not been replicated in at least one study.
The 11 replicated markers were:
- power/strength markers
- ACE Alu I/D (rs4646994) (called ACE D)
- ACTN3 Arg577
- AMPD1 Gln12
- HIF1A 582Ser
- MTHFR rs1801131 C
- NOS3 rs2070744 T
- PPARG 12Ala
The six GWAS markers were:
- CREM rs1531550 A,
- DMD rs939787 T
- GALNT13 rs10196189 G
- NFIA-AS1 rs1572312 C,
- RBFOX1 rs7191721 G
- TSHR rs7144481 C
The mainstream perspective is that gene doping is dangerous and unethical, as is any application of a therapeutic intervention for non-therapeutic or enhancing purposes, and that it compromises the ethical foundation of medicine and the spirit of sport. Others, who support human enhancement on broader grounds, or who see a false dichotomy between "natural" and "artificial" or a denial of the role of technology in improving athletic performance, do not oppose or support gene doping.
- Momaya A, Fawal M, Estes R (April 2015). "Performance-enhancing substances in sports: a review of the literature". Sports Med. 45 (4): 517–531. doi:10.1007/s40279-015-0308-9. PMID 25663250.
- World Anti-Doping Agency The World Anti-Doping Code: The 2008 Prohibited List of International Standards pages 7-8
- Barry, Patrick. 2008. Finding the golden genes. Science News 174, (3) (Aug. 2): 16-21
- Gretchen Reynolds for The New York Times. June 3, 2007. Outlaw DNA
- Gould D Gene doping: gene delivery for olympic victory. Br J Clin Pharmacol. 2013 Aug;76(2):292-8. PMID 23082866 PMC 3731603
- van der Gronde T, de Hon O, Haisma HJ, Pieters T. Gene doping: an overview and current implications for athletes. Br J Sports Med. 2013 Jul;47(11):670-8. Review. PMID 23322893
- Friedmann T, Koss JO. Gene transfer and athletics- an impending problem. Mol Ther. 2001 Jun;3(6):819-20.PMID 11407894 Free full text
- World Anti Doping Agency. Gene Doping Page archived January 7, 2016
- President’s Council on Bioethics April 25-26, 2002 Agenda, [https://bioethicsarchive.georgetown.edu/pcbe/background/workpaper7.html Working Paper 7
- President’s Council on Bioethics July 11-12, 2002 Meeting Agenda Session 4
- President’s Council on Bioethics September 12-13, 2002 Meeting Agenda Session 7: Enhancement 5: Genetic Enhancement of Muscle, H. Lee Sweeney, Ph.D., Professor and Chairman of Physiology, University of Pennsylvania
- Pearson, Sue; Jia, Hepeng; Kandachi, Keiko (2004). "China approves first gene therapy". Nature Biotechnology. 22 (1): 3–4. doi:10.1038/nbt0104-3. PMID 14704685.
- UCSD Public Relations: February 18, 2003 News Release: Bigger, Faster, Stronger: Genetic Enhancement and Athletics
- AdisInsight Vascular endothelial growth factor gene therapy - HSCI Page accessed June 5, 2016
- "Gene Therapy for PAD Approved". 6 December 2011. Retrieved 5 August 2015.
- Richards, Sabrina (6 November 2012). "Gene Therapy Arrives in Europe". The Scientist.
- Gallagher, James. (2 November 2012) BBC News – Gene therapy: Glybera approved by European Commission. BBC. Retrieved 15 December 2012.
- Birzniece V Doping in sport: effects, harm and misconceptions. Intern Med J. 2015 Mar;45(3):239-48. PMID 25369881
- Ahmetov II, Fedotovskaya ON. Current Progress in Sports Genomics. Adv Clin Chem. 2015;70:247-314. Review. PMID 26231489
- Cieszczyk, P., Maciejewska, A., Sawczuk, M. (2009). Gene Doping in Modern Sport. Biology of Exercise 5(1):5-14. doi:10.4127/jbe.2009.0021
- Haisma, H.J., & de Hon, O. (2006). Gene Doping. International Journal of Sports Medicine, 27, 257-266. doi: 10.1055/s-2006-923986. PMID 6572366
- Diamanti-Kandarakis, E., Konstantinopoulos, P. A., Papailiou, J., Kandarakis, S. A., Andreopoulos, A., & Sykiotis, G. P. (2005). Erythropoietin abuse and erythropoietin gene doping. Sports Medicine, 35(10), 831-840. PMID 16180943
- Oliveira, R.S., Collares, T.F., Smith, K.R., Seixas, F.K. (2011). The use of genes for performance enhancement: doping or therapy?. Brazilian Journal of Medical and Biological Research, 44 (12), 1194-1201 PMID 22030863 Free full text
- Perez IC et al. PCR-based detection of gene transfer vectors: application to gene doping surveillance. Anal Bioanal Chem. 2013 Dec;405(30):9641-53 .PMID 23912835
- Sweeney, H.L. (July 2004) “Gene Doping.” Scientific American, pp. 63-69.
- Kayser, B.; Mauron, A.; Miah, A. (2007). "Current anti-doping policy: A critical appraisal". BMC Medical Ethics. 8: 2. doi:10.1186/1472-6939-8-2. PMC . PMID 17394662.
- Friedmann T, Rabin O, Frankel MS. Ethics. Gene doping and sport. Science. 2010 Feb 5;327(5966):647-8. PMID 20133558
- Theodore Friedmann. 2010. How close are we to gene doping? Hastings Center Report 40(2):20-2 doi:10.1353/hcr.0.0246 PMID 20391845
- Miah, Andy (2004). Genetically Modified Athletes: Biomedical Ethics, Gene Doping and Sport. Routledge. ISBN 0-415-29880-6.
- Hilvoorde, I. van, Vos, R. & Wert, G. de (2007) Flopping, Klapping and Gene Doping; Dichotomies between ‘natural’ and ‘artificial’ in elite sport. In: Social Studies of Science 37/2 (April 2007) 173-200.